Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07804381) titled 'Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Yonsei University
Condition:
Parkinson Disease
Intervention:
Drug: Sitagliptin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 15, 2026
Target Sample Size: 160
To know more, visit https://clinicaltrials.gov/study/NCT07804381
Disclaimer: Curated by HT Syndicatio...